Chest Radiological Findings and Clinical Characteristics of Laboratory-Confirmed COVID-19 Patients from Saudi Arabia

**Background:** Coronavirus disease 2019 (COVID-19) is a viral respiratory disease that first emerged in China in December 2019 and quickly spread worldwide. As the prevalence of COVID-19 increases, radiological examination is becoming an essential diagnostic tool for identifying and managing the disease’s progression. Therefore, we aimed to identify the chest imaging features and clinical characteristics of patients with laboratory-confirmed COVID-19 in Saudi Arabia.

**Material/Methods:** In this retrospective study, data of laboratory-confirmed COVID-19 patients were collected from 4 hospitals in Jeddah, Saudi Arabia. Their common clinical characteristics, as well as imaging features of chest X-rays and computed tomography (CT) images, were analyzed.

**Results:** A total of 297 patients with laboratory-confirmed COVID-19 who underwent chest imaging were investigated in this study. Of these patients, 77.9% were male and 22.2% were female. Their mean age was 48 years old. The most common clinical symptoms were fever (187 patients; 63%) and cough (174 patients; 58.6%). The predominant descriptive chest imaging findings were ground-glass opacities and consolidation. Locations of abnormalities were bilateral, mainly distributed peripherally, in the lower lung zones, and in the middle lung zones.

**Conclusions:** This study provides an understanding of the most common clinical and radiological features of patients with laboratory-confirmed COVID-19 in Saudi Arabia. The majority of COVID-19 patients in our study cohort had either stable or worse progression of lung lesions during follow-ups; thus, they presented moderate disease cases. Elderly males were more affected by COVID-19 than females, with fever and cough being the most common clinical symptoms.

**Keywords:** COVID-19 • Multidetector Computed Tomography • Radiography

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/932441
Background

Coronavirus disease 2019 (COVID-19) is a viral respiratory disease that first emerged in Wuhan, China, in December 2019. It quickly spread worldwide with increasing numbers of infected people and deaths [1,2]. Accordingly, the World Health Organization declared it a public health emergency of international concern on January 30, 2020 [3]. As of March 2, 2020, the Ministry of Health in Saudi Arabia confirmed the first case of COVID-19 in the kingdom [4,5]. By May 20, 2021, more than 437 569 cases, including 7214 deaths from COVID-19, had been recorded in Saudi Arabia [6]. Early diagnosis and detection are important to isolate suspected COVID-19 cases and control the outbreak [7].

The most common clinical symptoms of COVID-19 are fever, cough, and shortness of breath [8-10]. These symptoms may appear 3-6 days after exposure, based on the virus’s incubation period of 0-14 days being assumed by the World Health Organization [11]. The current criterion standard diagnostic tool for COVID-19 is the reverse transcription polymerase chain reaction (RT-PCR) analysis extracted from a saliva or mucus swab sample [12]. However, there are a number of variables affecting their sensitivity in clinical practice, including the stage of infection, specimen type and handling, and the sufficiency of the specimen [13,14]. Thus, suspected COVID-19 cases need to be isolated during the RT-PCR test processing time to reduce the risk of disease transmission [13,14]. In addition, the main concern during a pandemic is about the availability of RT-PCR testing. Therefore, chest radiological examinations with CT and/or X-rays have been used in several studies along with RT-PCR testing for the early diagnosis and management of COVID-19 progression [7,9,12,15-20].

Recently, most of the published studies of chest imaging findings in patients with COVID-19 have been exclusively based in China and focused on CT manifestations [2,15,16,18,21-30]. To the best of our knowledge, information regarding imaging features of patients infected with COVID-19 in the Saudi Arabian population is scarce. In this study, we aimed to explore the chest imaging findings and clinical characteristics of patients with laboratory-confirmed COVID-19 admitted to government hospitals in Jeddah, Saudi Arabia.

Material and Methods

Study Design and Participants

This was a retrospective, multi-center case series study that included 305 laboratory-confirmed COVID-19 cases. Data related to COVID-19 cases were collected from 4 government institutions (King Fahad General Hospital, King Abdullah Medical Complex, East Jeddah Hospital, and King Abdul-Aziz Hospital) in Jeddah, Saudi Arabia, from May 15 to July 10, 2020. Inclusion criteria were patients being at least 18 years old, having laboratory confirmation of COVID-19 infection via real-time RT-PCR, and having undergone a chest radiological examination. We excluded all suspected cases without evidence of laboratory confirmation of COVID-19 infection despite having symptoms or patients who had positive RT-PCR results but were discharged for home isolation without diagnosis via chest imaging.

Data Collection

Information on patient demographics, signs and symptoms, co-morbid medical conditions, laboratory results, and radiological findings retrospectively extracted from patients’ paper and electronic medical records were collected by research coordinators and cross-checked by research investigators. All data were collected at the time of the patient’s admission. The patients’ medical record numbers were hidden from the data header to ensure the confidentiality of all data.

Through laboratory investigation, amplification of the genetic material was extracted from the saliva or mucus swab sample through an RT-PCR. The final results were categorized as negative or positive in the study analysis. The date of disease onset was defined as the day when the first symptom was noticed.

The COVID-19 disease severity was classified into mild, moderate, and severe cases based on laboratory, clinical, and radiological findings. Laboratory-confirmed COVID-19 patients asymptomatic or with clinical symptoms and an absence of radiological findings of pneumonia were classified as mild cases. Moderate cases were defined as laboratory-confirmed COVID-19 patients with clinical symptoms and the presence of radiographic signs of pneumonia. Severe cases were defined as laboratory-confirmed COVID-19 patients with severe clinical symptoms or critically ill COVID-19 patients admitted to intensive care units (ICU) due to respiratory failure requiring invasive mechanical ventilation, organ failure, or shock and the presence of more severe radiographic signs such as pulmonary infiltration > 50% of the lung field.

Radiological Assessment

Chest X-rays were acquired in the routine postero-anterior projection with full inspiration or in the antero-posterior projection in cases of supine patients using digital or portable chest X-ray machines. All laboratory-confirmed COVID-19 patients in our study cohort were initially screened with chest X-rays. CT scans were only performed for evaluation of progressed severe cases during follow-ups or for assessment of complications of COVID-19 pneumonia. CT imaging was performed using a multi-detector CT scanner with 64 channels with the...
following scanners: Somatom Emotion (Siemens Healthcare), HiSpeed-Dual (GE Healthcare), and 64-MDCT LightSpeed VCT (GE Healthcare). The acquisition parameters for CT examinations were as follows: tube voltage, 120 kVp; 100-150 mAs; collimation, 0.625-5 mm; pitch, 0.75-1.5; and image reconstruction (slice thickness, 1.25 mm/interval, 1.25 mm). All scans were done from the upper level of the thoracic inlet to the inferior level of costophrenic angle. CT examinations were conducted without a contrast medium with the patient in supine position at full inspiration. To further examine pulmonary embolism, CT pulmonary angiograms were performed with intravenous contrast administration.

All radiological examinations, including chest X-rays and CT scans or follow-up examinations performed for confirmed COVID-19 patients, were interpreted by consultant radiologists with more than 10 years of experience in chest imaging. Consultant radiologists were blinded to the subjects’ clinical outcomes. Then, the radiological images were determined to be normal or abnormal. A normal chest image was defined as being devoid of lung opacities and the absence of pleural effusion and pneumothorax. Chest images with opacities were considered abnormal and were assessed for predominant distribution of opacities and patterns.

Radiological images, including chest X-rays and CT scans, were evaluated for the presence of the following features: lung opacities that could be ground-glass opacities and/or consolidation, pleural effusion or pneumothorax, linear atelectasis, reticulation, distribution within the lung (peripheral, perihilar, central, or diffuse), laterality (right, left, or bilateral), involved lung field (upper, lower, or middle zones), and their progression on follow-up images (stable, worse, or improved). Other radiological features were also investigated, such as peribronchial wall thickening, pulmonary embolism, air bronchogram signs, interlobular septal thickening, subpleural, mediastinal lymphadenopathy, and pulmonary nodules.

**Ethical Consideration**

This study was approved by the institutional review board at the Ministry of Health in Saudi Arabia, registration number KACST, KSA: H-02-J-002. Patients were informed that their personal information will be kept confidential and their clinical data and radiological images will be used for research purposes in this project. A written consent form was waived due to the retrospective, observational nature of the study.

**Statistical Analysis**

Statistical analysis was performed using SPSS version 25.0 (IBM). Descriptive statistical analysis was used to describe patients’ demographics, clinical characteristics, radiological findings, and laboratory findings. The independent samples t test was used to compare categorical variables of disease severity in the present study. Categorical variables were presented as numbers (n) and percentages (%). Continuous variables were presented as mean±standard deviation values.

### Table 1. Demographic and clinical characteristics of patients with COVID-19.

| Characteristics                  | n=297 |
|----------------------------------|-------|
| **Age group**                    |       |
| 18-25                            | 12 (4) |
| 26-35                            | 49 (16.5) |
| 36-45                            | 59 (19.9) |
| 46-55                            | 91 (30.6) |
| 56-65                            | 51 (17.2) |
| >66                              | 35 (11.8) |
| **Gender**                       |       |
| Male                             | 231 (77.9) |
| Female                           | 66 (22.2) |
| **Clinical symptoms**            |       |
| Fever                            | 187 (63) |
| Cough                            | 174 (58.6) |
| Sputum                           | 9 (3) |
| Sore throat                      | 25 (8.4) |
| Running nose                     | 6 (2) |
| Diarrhea                         | 20 (6.7) |
| Dyspnea                          | 56 (18.9) |
| Headache                         | 17 (5.7) |
| Nausea and vomiting              | 13 (4.4) |
| Asymptomatic                     | 39 (13.1) |
| **Comorbidities**                |       |
| Diabetes                         | 28 (9.4) |
| Hypertension                     | 27 (9.1) |
| Hypothyroidism                   | 2 (0.7) |
| Renal disease                    | 1 (0.3) |
| Chronic liver disease            | 1 (0.3) |
| **COVID-19 disease severity**    |       |
| Mild                             | 82 (27.6) |
| Moderate                         | 187 (63) |
| Severe                           | 28 (9.4) |
Results

Demographic and Clinical Characteristics

The original study cohort of COVID-19 cases included 311 participants. Of these participants, a total of 297 who had laboratory-confirmed COVID-19 patients and who underwent chest imaging were included in our study analysis. Demographic and clinical characteristics of all patients included in the present study are summarized in Table 1. The mean (± standard deviation) age of patients was 48 (±14.3) years. The majority of patients who had positive RT-PCR results were in the age range of 46-55 (Figure 1), and among males (n=155) more than females (n=32) (Figure 2).

Radiological Findings

Tables 2 and 3 provide the chest imaging finding of laboratory-confirmed COVID-19 patients. The majority of COVID-19 patients had abnormal radiological findings, bilateral in nature, of which ground-glass opacities and consolidations were most frequent, mainly involved within the lower and middle

| Table 2. Radiological findings on chest X-rays (n=297). |
| --- |
| **Characteristics** | **No. of findings (%)** |
| Normal baseline chest x-ray | 74 (24.9) |
| Abnormal baseline chest x-ray | 223 (75.1) |
| Follow-up chest x-ray | 172 (57.9) |
| Normal baseline chest x-ray later becoming abnormal | 13 (4.4) |
| Predominate findings on chest x-rays |  |
| Ground-glass opacity | 226 (76.1) |
| Consolidation | 49 (16.5) |
| Distribution within the lung |  |
| Peripheral | 116 (39.1) |
| Perihilar | 21 (7.1) |
| Central | 5 (1.7) |
| Diffuse | 32 (10.8) |
| Shape of the lesions |  |
| Patchy | 18 (6) |
| Nodular | 5 (2) |
| Location |  |
| Unilateral right | 39 (13.1) |
| Unilateral left | 27 (9.4) |
| Bilateral | 157 (57.2) |
| Zonal predominance |  |
| Upper zone | 19 (6.4) |
| Lower zone | 136 (45.8) |
| Middle zone | 108 (36.4) |
| Other imaging features |  |
| Reticulation | 3 (1) |
| Linear atelectasis | 25 (8.4) |
| Pleural effusion | 35 (11.8) |
| Pneumothorax | 8 (2.7) |
| Pulmonary nodules | 5 (1.7) |
| Bronchovascular markings | 28 (9.4) |
| Progression during follow-ups* |  |
| Improved | 25 (14.5) |
| Stable | 69 (40.2) |
| Worse | 78 (45.3) |

* Percentage were calculated on the basis of 172 patients who had follow-up chest x-ray.
lung zones. The predominate chest X-ray findings is shown in Figure 3.

The pulmonary involvement of lung lesions on chest CT images of COVID-19 patients most commonly found in multiple lung zones (middle and lower lung zones), bilaterally and peripherally distributed (Table 3). Seven patients (33.3%) presented with diffuse scattered patchy ground-glass opacities and/or consolidations within the lung. None of our participants had only central distribution and 4 patients had no axial lung distribution on CT images (Table 3). Figures 4A, 4B and 5A-5C show the predominate chest CT imaging features of laboratory-confirmed COVID-19 patients.

Other imaging features found on chest CT images of COVID-19 patients were air bronchogram signs (52.4%), atelectasis (42.9%), and subpleural lines (33.3%). Pleural effusion, pneumothorax, pulmonary nodules, and pulmonary embolism were found in a small number of patients (Table 3). Mediastinal lymphadenopathy was less common in COVID-19 patients.

Discussion

The present study found that most patients with laboratory-confirmed COVID-19 had typical imaging features, including ground-glass opacity lesions and consolidation, that are peripherally distributed, bilaterally involved, and predominantly in the lower and middle lung zones. In addition, the majority of COVID-19 patients in our study cohort had either stable or worse progression of lung lesions during follow-ups; thus, they presented moderate disease cases. The most common clinical symptoms were fever and cough. The mean age group infected with COVID-19 was 41-60 years, and males were affected more than females.

Chest imaging plays an important role in the diagnosis of COVID-19 [7,17,31]. Radiological features such as ground-glass opacity and consolidation that were present in our study cohort are similar to those of the imaging features of COVID-19 presented in previously published studies in China and other countries [15,18,19,26,29,32-37]. These are the hallmarks of COVID-19 in chest X-rays and CT imaging [18,29,32,37,38]. Regarding lesion distribution, patients with laboratory-confirmed COVID-19 in the present study were more likely to have peripheral distribution, bilateral involvement, and lower and

| Predominate chest CT findings | No. of findings (%) |
|------------------------------|---------------------|
| Ground-glass opacity         | 18 (81.8)           |
| Consolidation                | 20 (90.9)           |
| No abnormalities             | 1 (4.5)             |

| Distribution within the lung | n (%) |
|------------------------------|-------|
| Peripheral                   | 10 (47.6) |
| Central                      | 0 (0)   |
| Diffuse                      | 7 (33.3) |
| No distribution              | 4 (19)  |

| Location                     | n (%) |
|------------------------------|-------|
| Unilateral right             | 4 (19) |
| Unilateral left              | 5 (23.8) |
| Bilateral                    | 12 (54.5) |

| Zonal predominance           | n (%) |
|------------------------------|-------|
| Upper zone                   | 3 (13.6) |
| Lower zone                   | 11 (50) |
| Middle zone                  | 10 (45.5) |

| Other imaging features       | n (%) |
|------------------------------|-------|
| Pleural effusion             | 4 (19) |
| Pneumothorax                 | 5 (23.8) |
| Pulmonary nodules            | 4 (19) |
| Atelectasis                  | 9 (42.9) |
| Peribronchial wall thickening| 6 (28.6) |
| Pulmonary embolism           | 5 (23.8) |
| Subpleural lines             | 7 (33.3) |
| Mediastinal lymphadenopathy  | 2 (9.5) |

Figure 3. Chest X-ray of a patient with laboratory-confirmed COVID-19 shows bilateral patchy ground-glass opacities (digital portable X-ray machine: Siemens mobilett mira).

Table 3. Chest CT findings (n=22).
middle lung predominance in chest imaging, which is consistent with results of previous studies [15,34,37-39].

The chest X-ray is considered a routine imaging modality for diagnosis and monitoring the care of patients with COVID-19 [17]. It helps in evaluating lung abnormalities for screening out patients with positive RT-PCR screening results [15,29]. Despite chest CT scans having high sensitivity for the early identification of lung lesions and diagnosis of patients with COVID-19 [19,21,40], only a few patients in our study cohort had chest CT examinations. Most of these patients were initially screened with chest X-rays and then had CT scans when they progressed to severe cases during follow-ups.

According to the American College of Radiology, CT scans are not recommended for use as a first-line test for the diagnosis of COVID-19 [41]. Therefore, CT scans can only be performed after the detection of abnormalities in chest X-rays of laboratory-confirmed COVID-19 patients or after screening patients with COVID-19 pneumonia complications [17,42,43]. Portable chest X-ray units are usually used for patients with COVID-19 to reduce infection risks in radiology departments [29].

Fever, cough, and dyspnea were the most common clinical symptoms in COVID-19 patients in our cohort. These clinical symptoms are in line with findings from a recent study by Saleemi et al [44] in Riyadh, Saudi Arabia. Their study found that 59% of COVID-19 patients had fever, cough, and dyspnea as their main symptoms.

Figure 4. (A) CT scan of patient with laboratory-confirmed COVID-19 shows bilateral scattered areas of peripheral consolidation and ground-glass opacities (CT scan: GE discovery CT750 hd). (B) CT scan of patient with laboratory-confirmed COVID-19 shows minimal interlobular septal thickening and right upper perihilar consolidation with air bronchogram (CT scan: GE discovery CT750 hd).
their COVID-19 patients had mild COVID-19, whereas 41% were categorized as severe cases [44]. Compared with that study, our study consisted of a larger number of hospitalized COVID-19 patients from different government hospitals in Jeddah, Saudi Arabia. In addition, we categorized the patients as mild, moderate, and severe COVID-19 cases. We found that the majority of laboratory-confirmed COVID-19 patients (63%) were moderate cases, whereas only 27.6% were mild and 9.4% were severe cases. Notably, 39 cases (13.1%) of confirmed positive COVID-19 in our study cohort were asymptomatic. This result suggests that laboratory tests and/or chest imaging should be done for asymptomatic individuals who are at high risk due to a history of contact with positive or suspected COVID-19 patients for early detection of the disease [34,42,45].

In the present study, we observed a greater number of males infected with COVID-19 than females, and most of the male cases were moderate. This finding is in agreement with previously published studies [9,46]. More males have also been found to be infected with the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus infection (SARS-CoV) than females [47,48].

**Figure 5.** (A) CT pulmonary angiogram with intravenous contrast administration of a patient with COVID-19 shows bilateral scattered areas of peripheral consolidation, and ground-glass opacities (CT scan: GE discovery CT750 hd). (B) CT pulmonary angiogram with intravenous contrast administration of a patient with COVID-19 shows a filling defect noted in the left lower lobar artery (CT scan: GE discovery CT750 hd). (C) CT pulmonary angiogram with intravenous contrast administration of a patient with COVID-19 shows a filling defect extending to the segmental branches (CT scan: GE discovery CT750 hd).
The protection of steroid hormones and factors related to sex chromosomes play an important role in innate and adaptive immunity, which reduces the susceptibility of females to viral infection [49–51]. Additionally, recent evidence revealed that high-risk lifestyle behaviors and preexisting comorbidities may also play a role in increased mortality and responses to COVID-19 among elderly men [52–54].

The main strength of our study is that it included a large number of participants with laboratory-confirmed COVID-19 from different government hospitals in Jeddah, Saudi Arabia. In addition, the study explored all the different radiological features from both chest X-rays and CT images. However, the study had some limitations. First, it included only positive laboratory-confirmed COVID-19 cases; negative results or suspected cases were not included in the analysis. Comprehensive investigation of the imaging features of suspected COVID-19 patients with negative results and confirmed positive results to differentiate COVID-19 pneumonia from other lung-infection diseases is recommended. Second, we did not have follow-up CT images in our cohort to explore changes in CT imaging features and compare them with clinical parameters for patients with severe cases. This could help in the management of disease progression and outcome prediction to support clinical decision making [39]. Further research is needed to evaluate the relationship between chest imaging features and clinical characteristics in COVID-19 cases in Saudi Arabia.

Conclusions

This study describes the radiology and clinical features of patients with confirmed COVID-19 in Saudi Arabia. The imaging pattern of laboratory-confirmed COVID-19 patients was bilateral peripheral ground-glass opacities and consolidation involving the lower and middle lung zones. Elderly males were more affected by COVID-19 than females, with fever and cough being the most common clinical symptoms. The present study demonstrates clinical and radiological characteristics of COVID-19 similar to previous studies reported worldwide. Our study suggests that combining evaluation of radiological features with laboratory and clinical findings could help in early diagnosis of COVID-19.

Acknowledgments

The authors thank Dr. Adnan Al-Homaidan, President of the University of Jeddah, and the Vice-President for Graduate Studies and Scientific Research, Dr. Obaid Al-Modaf, for their support and encouragement regarding research related to COVID-19. In addition, the authors would like to thank the College of Applied Medical Sciences and the Department of Applied Radiologic Technology in the University of Jeddah for their full support. We would also like to thank the technicians and radiologists in the Radiology Departments of the following hospitals: King Fahad General Hospital, King Abdullah Medical Complex, King Abdul-Aziz Hospital and Oncology Center, and East Jeddah General Hospital in Jeddah, Saudi Arabia, for their help in gathering the essential data for the study. We would like to thank the research center administrators at King Fahad General Hospital and East Jeddah General Hospital in Jeddah, Saudi Arabia, for their support of the research team.

Conflict of Interest

None declared.

Declaration of Figures Authenticity

All figures submitted have been created by the authors, who confirm that the images are original with no duplication and have not been previously published in whole or in part.

References:

1. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: Key points for the radiologist. Radiology. 2020;295(1):16–17
2. Zhou S, Wang Y, Zhu T, Xia L. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. Am J Roentgenol. 2020;214(6):1287–94
3. Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76 [Erratum in: Int J Surg. 2020 May;77: 217]
4. Barry M, Ghenem L, Alsharidi A, et al. Coronavirus disease-2019 pandemic in the Kingdom of Saudi Arabia: Mitigation measures and hospital preparedness. Journal of Nature and Science of Medicine. 2020;3(3):155
5. Barry M, Al Amri M, Memish ZA. COVID-19 in the Shadows of MERS-CoV in the Kingdom of Saudi Arabia. J Epidemiol Glob Health. 2020;10(1):1–3
6. Ministry of health in Saudi Arabia https://covid19.moh.gov.sa [In Arabic]
7. Yang W, Sirajuddin A, Zhang X, et al. The role of imaging in 2019 novel coronavirus pneumonia (COVID-19). Eur Radiol. 2020;30(9):4874–82
8. Zhang G, Zhang J, Wang B, et al. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A retrospective analysis. Respir Res. 2020;21(1):74
9. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet (London, England). 2020;395(10223):507–13
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497–506
11. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Eurosurveillance. 2020;25(5):2000062
12. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020;126:108961
13. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020;92(7):903–8

© Med Sci Monit, 2021; 27: e932441
14. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology. 2020;296(2):E32-40

15. Wong HYF, Lam HYS, Fong AH-T, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology. 2020;296(2):E72-78

16. Wang K, Kang S, Tian R, et al. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiangyan area. Clin Radiol. 2020;75(5):341-47

17. Rubin GD, Ryerson CJ, Harnamti LB, et al. The role of chest imaging in patient management during the COVID-19 pandemic: A multicenter consensus statement from the fleischner society. Chest. 2020;158(1):106-16

18. Kong W, Agarwal PP. Chest imaging appearance of COVID-19 infection. Radiol Cardiothorac Imaging. 2020;2(1):e200028

19. Ng M-Y, Lee EY, Yang J, et al. Imaging profile of the COVID-19 infection: Radiologic findings and literature review. Radiol Cardiothorac Imaging. 2020;2(1):e200034

20. Shahzeb M, Khan A, Muhammad A. Detection of coronavirus disease (COVID-19) using radiological examinations. J Pure Appl Microbiol. 2020;14:911-20, 20200429

21. Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): A study of 63 patients in Wuhan, China. Eur Radiol. 2020;30(6):3306-9

22. Xu YH, Dong JH, An WM, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect. 2020;80(4):394-400

23. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388-93

24. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. CT scans of patients with 2019 novel coronavirus (COVID-19) pneumonia. Theranostics. 2020;10(10):4606

25. Zhong Q, Li Z, Shen X, et al. [CT imaging features of patients with different clinical types of coronavirus disease 2019 (COVID-19)]. Zhonghua Jie Pu Xin Bi Yan Xue Bao Yi Xue Ban. 2020;49(1):198-202 [in Chinese]

26. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV), Radiology. 2020;295(1):202-7

27. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease-19 (COVID-19): A pictorial review. Clin Imaging. 2020;64:35-42

28. Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020;47(5):1275-80

29. Zhao W, Zhong Z, Xie X, et al. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: A multicenter study. Am J Roentgenol. 2020;214(5):1072-77

30. Li B, Li X, Wang Y, Han Y, et al. Diagnostic value and key features of computed tomography in coronavirus disease 2019. Emerg Microbes Infect. 2020;9(1):787-93

31. Radiology ACo. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. ACR website. 2020

32. Shirani K, Sheikhhaeili E, Torkpour Z, et al. A narrative review of COVID-19: the new pandemic disease. Iran J Med Sci. 2020;45(5):233-49

33. Rapits CA, Hammer MM, Short RG, et al. Chest CT and coronavirus disease (COVID-19): A critical review of the literature to date. Am J Roentgenol. 2020;215(4):839-42

34. Saleemi S, Alhajji M, Almaghrabi R. Clinical characteristics of patients with COVID-19 in Saudi Arabia—a single center experience. Res Rev Infect Dis. 2020;3(1):68-74

35. Feng Z, Yu Q, Yao S, et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun. 2020;11(1):1-9

36. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus – infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-69

37. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-33

38. Channappanavar R, Fett C, Mack M, et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198(10):4046-53

39. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol. 2019;56(3):308-21

40. Conti P, Younes A. Coronavirus CDV-19/SARS-CoV-2 affects women less than men: Clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34(2):393-43

41. Papadopoulos V, Li L, Samplaski M. Why does COVID-19 kill more elderly men than women? Is there a role for testosterone? Andrology. 2021;9(1):65-72

42. Griffith DM, Sharma G, Holliday CS, et al. Men and COVID-19: a biopsychosocial approach to understanding sex differences in mortality and recommendations for practice and policy interventions. Prev Chronic Dis. 2020;17:E63

43. Hatao T, Vermunt J, Abeykoon J, et al. (eds.), COVID-19 and sex differences: Mechanisms and biomarkers. Elsevier, Mayo Clinic Proceedings, 2020

44. Agrawal H, Das N, Nathani S, et al. An assessment on impact of COVID-19 infection in a gender specific manner. Stem Cell Res Rep. 2021;17(1):94-112